HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vertigo, particularly of vascular origin, treated with flunarizine (R 14 950).

Abstract
The antivertiginous properties of 1-[bis(p-fluorophenyl)-methyl]-4-cinnamylpiperazine (flunarizine, R 14 950) were evaluated in three consecutive studies -- two open and one double-blind -- in a total of 99 patients showing definite vertigo. Dosage was two tablets (= 20 mg) t.i.d. for three days in Study I (50 patients), 20 mg t.i.d. for two months in Study II (31 patients), and weekly decreasing doses of four, three, two and one (maintenance) tablets of flunarizine or placebo for three months in Study III (9/18 patients with vertigo of recent origin). Improvement of vertigo was significant both objectively and subjectively in Studies I and II. In Study III, objective tests were always clearly in favour of flunarizine, but subjectively, flunarizine was superior only by month two. Vertigo of vascular origin seemed to be a preferential indication for flunarizine treatment. No major side-effects were found in these studies.
AuthorsR Boniver
JournalArzneimittel-Forschung (Arzneimittelforschung) Vol. 28 Issue 10 Pg. 1800-4 ( 1978) ISSN: 0004-4172 [Print] Germany
PMID582686 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • Piperazines
  • Placebos
Topics
  • Adolescent
  • Adult
  • Aged
  • Cerebrovascular Disorders (complications)
  • Double-Blind Method
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Male
  • Middle Aged
  • Piperazines (therapeutic use)
  • Placebos
  • Time Factors
  • Vertigo (drug therapy, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: